KYBELLA
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- KYBELLA
- Generic name
- DEOXYCHOLIC ACID
- Manufacturer
- Kythera Biopharmaceuticals Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553
- SPL ID
- 8125c34a-6f8e-47d8-bcd2-1b8cf1ce8a7a
- Version
- 26
- Effective date
- 2026-09-11
- Source export date
- 2026-11-13
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:34:57
| Harmonized routes |
|---|
| SUBCUTANEOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 206333 | derived:openfda.application_number |
| application number | NDA206333 | openfda.application_number | |
| brand name | KYBELLA | openfda.brand_name | |
| generic name | DEOXYCHOLIC ACID | openfda.generic_name | |
| manufacturer name | Kythera Biopharmaceuticals Inc. | openfda.manufacturer_name | |
| ndc | package | 61168-101-91 | openfda.package_ndc |
| ndc | package | 61168-101-04 | openfda.package_ndc |
| ndc | package | 61168-101-94 | openfda.package_ndc |
| ndc | package | 61168-101-01 | openfda.package_ndc |
| ndc | package | 61168-101-03 | openfda.package_ndc |
| ndc | product | 61168-101 | openfda.product_ndc |
| ndc11 | package | 61168010194 | derived:openfda.package_ndc |
| ndc11 | package | 61168010104 | derived:openfda.package_ndc |
| ndc11 | package | 61168010101 | derived:openfda.package_ndc |
| ndc11 | package | 61168010103 | derived:openfda.package_ndc |
| ndc11 | package | 61168010191 | derived:openfda.package_ndc |
| rxcui | 1649975 | openfda.rxcui | |
| rxcui | 1649980 | openfda.rxcui | |
| spl id | 8125c34a-6f8e-47d8-bcd2-1b8cf1ce8a7a | id | |
| spl set id | fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553 | set_id | |
| unii | 005990WHZZ | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PR E CAUTIONS Marginal Mandibular Nerve Injury : Follow injection technique and do not inject KYBELLA into or in close proximity to the marginal mandibular branch of the facial nerve to avoid this injury. ( 2.3 , 5.1 ) Dysphagia : May occur with KYBELLA use. Avoid use in patients with pre-existing dysphagia because use may exacerbate the condition. ( 5.2 ) Injection Site Reactions ( 5.3 ): Hematoma/Bruising: Use KYBELLA with caution in patients with bleeding abnormalities (e.g., taking antiplatelet or anticoagulant therapy). Alopecia: Consider withholding subsequent KYBELLA treatments until resolution. Ulceration, Necrosis, Nodule, Mass, and Infection: Discontinue KYBELLA if patients develop injection site ulceration, necrosis, nodule, mass, or infection after KYBELLA administration. Risk of Injecting in Proximity to Vulnerable Anatomic Structures: Avoid injecting in proximity to vulnerable anatomic structures due to the increased risk of tissue damage and vascular injury. ( 2.3 , 5.4 ) Serious Adverse Reactions Associated with Unapproved Use Outside the Submental Region: Serious adverse reactions have been reported following unapproved administration of KYBELLA outside the submental region. KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region. ( 5.5 ) 5. 1 Marginal Mandibular Nerve Injury Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness (paresis), were reported in KYBELLA-treated patients during clinical trials. All marginal mandibular nerve injuries reported from the trials resolved without additional treatment (range 1-298 days, median 44 days). To avoid the potential for marginal mandibular nerve injury, do not inject KYBELLA into or in close proximity to the marginal mandibular branch of the facial nerve [see Dosage and Administration ( 2.3 )]. 5 . 2 Dysphagia Difficulty swallowing (dysphagia) occurred in KYBELLA-treated patients in clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area. Cases of dysphagia resolved without additional treatment (range 1-81 days, median 3 days). Subjects with current or prior history of dysphagia were excluded from clinical trials. Avoid use of KYBELLA in patients with a current or prior history of dysphagia because KYBELLA use may exacerbate the condition. 5.3 Injection Site Reactions Injection Site Hematoma or Bruising In clinical trials, 72% of subjects treated with KYBELLA had an injection site hematoma or bruising [see Adverse Reactions ( 6.1 ) ] . Use KYBELLA with caution in patients with bleeding abnormalities (e.g., taking antiplatelet or anticoagulant therapy) as excessive bleeding or bruising in the treatment area may occur. Injection Site Alopecia Cases of injection site alopecia have been reported with KYBELLA administration. The onset and duration of this adverse reaction may vary among individuals and may persist. Consider withholding subsequent KYBELLA treatments until resolution of this adverse reaction. Injection Site Ulceration, Necrosis, Nodule, Mass, and Infection Very superficial injections (into the dermis) of KYBELLA may result in skin ulceration and necrosis [see Dosage and Administration ( 2.3 )] . Cases of injection site ulceration, necrosis, nodule (≤ 3 cm in diameter), mass (> 3 cm in diameter), and infection have been reported with KYBELLA administration. Nodules or masses may occur following initial or subsequent KYBELLA administration. Some nodules and masses may not resolve and medical intervention may be required. Some cases of injection site infection have included cellulitis and abscess requiring intravenous antibiotic treatment and incision and drainage. Discontinue KYBELLA if patients develop injection site ulceration, necrosis, nodule, mass, or infection after KYBELLA administration. 5.4 Risk of Injecting in Proximity to Vulnerable Anatomic Structures To avoid potential tissue damage, do not inject KYBELLA into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles. Avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury. 5.5 Serious Adverse Reactions Associated with Unapproved Use Outside the Submental Region Serious adverse reactions have been reported following unapproved administration of KYBELLA outside the submental region (e.g., blurred or reduced vision with periorbital use, muscle or nerve injury including facial paresis and paresthesia). Cases of injection site nodules (≤ 3 cm in diameter) and masses (> 3 cm in diameter) have also been reported following initial or subsequent administration of KYBELLA outside the submental region. The nodules and masses may not resolve and medical intervention may be required. KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region [see Indications and Usage ( 1 )].
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (>20% of subjects) include injection site edema/swelling, hematoma, pain, numbness, erythema and induration. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6 . 1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In two double-blind, placebo-controlled clinical trials 513 subjects were treated with KYBELLA and 506 subjects were treated with placebo [see Clinical Studies ( 14 )]. Subjects received up to 6 treatments at least 1 month apart and were followed for up to 6 months after the last received treatment. The most commonly reported adverse reactions are listed below ( Table 1 ). Table 1. Adverse Reactions in the Pooled Trials 1 and 2 a Adverse reactions KYBELLA (N=513) n (%) Placebo (N=506) n (%) Injection site reactions 492 (96%) 411 (81%) edema/swelling 448 (87%) 218 (43%) hematoma/bruising 368 (72%) 353 (70%) pain 356 (70%) 160 (32%) numbness 341 (66%) 29 (6%) erythema 136 (27%) 91 (18%) induration 120 (23%) 13 (3%) paresthesia 70 (14%) 20 (4%) nodule 68 (13%) 14 (3%) pruritus 64 (12%) 30 (6%) skin tightness 24 (5%) 6 (1%) site warmth 22 (4%) 8 (2%) nerve injury b 20 (4 %) 1 (<1%) Headache 41 (8%) 20 (4%) Oropharyngeal pain 15 (3%) 7 (1%) Hypertension 13 (3%) 7 (1%) Nausea 12 (2%) 3 (1%) Dysphagia 10 (2%) 1 (<1%) a Adverse reactions that occurred in ≥ 2% KYBELLA treated subjects and at greater incidence than placebo b Marginal mandibular nerve paresis Other adverse reactions associated with the use of KYBELLA included injection site hemorrhage, injection site discoloration, pre-syncope/syncope, lymphadenopathy, injection site urticaria, and neck pain. Adverse reactions that lasted more than 30 days and occurred in more than 10% of KYBELLA-treated subjects were injection site numbness (42%), injection site edema/swelling (20%), injection site pain (16%), and injection site induration (13%). 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of KYBELLA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA exposure. Administration Site Conditions : injection site ulceration, necrosis, mass, infection, alopecia, and scarring. Immune System Disorders: Hypersensitivity reactions including rash, urticaria, and itching. Nervous System Disorders: Oral hypoaesthesia and oral paraesthesia. Procedural Complications: Vascular injury due to inadvertent intravascular injection.
adverse reactions table
<table ID="Table1"> <caption>Table 1. Adverse Reactions in the Pooled Trials 1 and 2<sup>a</sup> </caption> <col width="147"/> <col width="109"/> <col width="126"/> <tbody> <tr> <td styleCode="Toprule Lrule Rrule "> <content styleCode="bold">Adverse reactions</content> </td> <td styleCode="Toprule Lrule Rrule " align="center"> <content styleCode="bold">KYBELLA</content> <content styleCode="bold">(N=513)</content> <content styleCode="bold">n (%)</content> </td> <td styleCode="Toprule Lrule Rrule " align="center"> <content styleCode="bold">Placebo</content> <content styleCode="bold">(N=506)</content> <content styleCode="bold">n </content> <content styleCode="bold">(%)</content> </td> </tr> <tr> <td styleCode="Toprule Lrule Rrule ">Injection site reactions</td> <td styleCode="Toprule Lrule Rrule " align="center">492 (96%)</td> <td styleCode="Toprule Lrule Rrule " align="center">411 (81%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule "> edema/swelling</td> <td styleCode="Toprule Lrule Rrule " align="center">448 (87%)</td> <td styleCode="Toprule Lrule Rrule " align="center">218 (43%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule "> hematoma/bruising</td> <td styleCode="Toprule Lrule Rrule " align="center">368 (72%)</td> <td styleCode="Toprule Lrule Rrule " align="center">353 (70%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule "> pain</td> <td styleCode="Toprule Lrule Rrule " align="center">356 (70%)</td> <td styleCode="Toprule Lrule Rrule " align="center">160 (32%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule "> numbness</td> <td styleCode="Toprule Lrule Rrule " align="center">341 (66%)</td> <td styleCode="Toprule Lrule Rrule " align="center">29 (6%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule "> erythema</td> <td styleCode="Toprule Lrule Rrule " align="center">136 (27%)</td> <td styleCode="Toprule Lrule Rrule " align="center">91 (18%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule "> induration</td> <td styleCode="Toprule Lrule Rrule " align="center">120 (23%)</td> <td styleCode="Toprule Lrule Rrule " align="center">13 (3%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule "> paresthesia</td> <td styleCode="Toprule Lrule Rrule " align="center">70 (14%)</td> <td styleCode="Toprule Lrule Rrule " align="center">20 (4%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule "> nodule</td> <td styleCode="Toprule Lrule Rrule " align="center">68 (13%)</td> <td styleCode="Toprule Lrule Rrule " align="center">14 (3%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule "> pruritus</td> <td styleCode="Toprule Lrule Rrule " align="center">64 (12%)</td> <td styleCode="Toprule Lrule Rrule " align="center">30 (6%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule "> skin tightness</td> <td styleCode="Toprule Lrule Rrule " align="center">24 (5%)</td> <td styleCode="Toprule Lrule Rrule " align="center">6 (1%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule "> site warmth</td> <td styleCode="Toprule Lrule Rrule " align="center">22 (4%)</td> <td styleCode="Toprule Lrule Rrule " align="center">8 (2%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule "> nerve injury<sup> b</sup> </td> <td styleCode="Toprule Lrule Rrule " align="center">20 (4 %)</td> <td styleCode="Toprule Lrule Rrule " align="center">1 (<1%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule ">Headache</td> <td styleCode="Toprule Lrule Rrule " align="center">41 (8%)</td> <td styleCode="Toprule Lrule Rrule " align="center">20 (4%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule ">Oropharyngeal pain</td> <td styleCode="Toprule Lrule Rrule " align="center">15 (3%)</td> <td styleCode="Toprule Lrule Rrule " align="center">7 (1%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule ">Hypertension</td> <td styleCode="Toprule Lrule Rrule " align="center">13 (3%)</td> <td styleCode="Toprule Lrule Rrule " align="center">7 (1%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule ">Nausea</td> <td styleCode="Toprule Lrule Rrule " align="center">12 (2%)</td> <td styleCode="Toprule Lrule Rrule " align="center">3 (1%)</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule ">Dysphagia</td> <td styleCode="Toprule Lrule Rrule " align="center">10 (2%)</td> <td styleCode="Toprule Lrule Rrule " align="center">1 (<1%)</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.